Literature DB >> 12203791

Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.

Sari Laitinen1, Ritva Karhu, Charles L Sawyers, Robert L Vessella, Tapio Visakorpi.   

Abstract

A major problem in studying prostate cancer has been the lack of model systems because of the difficulties in growing prostate cancer cells in vitro. Recently, however, several human prostate cancer xenografts, grown in immune-deficient mice, have been established. Here, we characterized 13 such xenografts (LuCaP 23.8, 23.12, 35, 41, 49, 58, 69, 70, 73, LAPC-4AD, LAPC-4AI, LAPC-9AD, and LAPC-9AI) as well as one prostate cancer cell line (22Rv1) derived from a xenograft for chromosomal alterations by comparative genomic hybridization and a modification of multicolor fluorescence in situ hybridization. On average, the xenografts contained 13 (range 5-28) aberrations, 5 (1-13) gains, and 8 (1-15) losses, per case. The chromosome arms that most often contained losses were 2q, 5q, 6q, 8p, 13q, and 18q, and gains were 7q, 8q, and Xq. The same regions were previously shown to be often altered in advanced prostate carcinomas in patients. The androgen-dependent and corresponding androgen-independent sublines of LAPC-4 and LAPC-9 shared all genetic alterations, suggesting that the transition of the growth from androgen dependency to independence does not involve major chromosomal aberrations in these two models. In conclusion, the identified genetic aberrations lay the groundwork for further detailed genetic analyses of these xenografts. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12203791     DOI: 10.1002/gcc.10097

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Human RecQL4 helicase plays critical roles in prostate carcinogenesis.

Authors:  Yanrong Su; Jarah A Meador; Gloria M Calaf; Luca Proietti De-Santis; Yongliang Zhao; Vilhelm A Bohr; Adayabalam S Balajee
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 2.  Patient-derived xenografts as in vivo models for research in urological malignancies.

Authors:  Takahiro Inoue; Naoki Terada; Takashi Kobayashi; Osamu Ogawa
Journal:  Nat Rev Urol       Date:  2017-02-21       Impact factor: 14.432

Review 3.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 4.  Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model?

Authors:  Lluis-A Lopez-Barcons
Journal:  Asian J Androl       Date:  2009-12-21       Impact factor: 3.285

5.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

6.  Molecular assays for the detection of microRNAs in prostate cancer.

Authors:  Amara C Siva; Luke J Nelson; Chad L Fleischer; Mehrdad Majlessi; Michael M Becker; Robert L Vessella; Mark A Reynolds
Journal:  Mol Cancer       Date:  2009-03-06       Impact factor: 27.401

Review 7.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

Review 8.  Patient-derived xenograft (PDX) models, applications and challenges in cancer research.

Authors:  Shahrokh Abdolahi; Zeinab Ghazvinian; Samad Muhammadnejad; Mahshid Saleh; Hamid Asadzadeh Aghdaei; Kaveh Baghaei
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440

9.  Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA.

Authors:  Dong Wang; Ivan Garcia-Bassets; Chris Benner; Wenbo Li; Xue Su; Yiming Zhou; Jinsong Qiu; Wen Liu; Minna U Kaikkonen; Kenneth A Ohgi; Christopher K Glass; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Nature       Date:  2011-05-15       Impact factor: 49.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.